Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium

Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease
Network WORLD Symposium

Conference Call on Friday, February 15 at 11:30am ET

CRANBURY, N.J., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced that 2 oral presentations and 5 posters related
to its investigational pharmacological chaperones will be included at the 9^th
Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held
February 13-15, 2013 in Orlando, FL. The Company will host a conference call
and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to
highlight the data presented at LDN WORLD.

Posters: Wednesday, February 13, 2013, 4:30-6:30pm ET and Thursday, February
14, 2013, 4:30-6:00pm ET

  A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat
  HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with
  Fabry Disease – D. Warnock, D. Bichet, M. Holida, O. Goker-Alpan, K.
  Nicholls, M. Thomas, F. Eyskens, S. Shankar, G. Linthorst, M. Dasouki, F. K.
  Johnson, P. Boudes

  A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating
  Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in
  Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M.
  Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T.
  Mozaffar, E. Finanger, F. Johnson, P. Boudes

  Exploring the Use of a Co-Formulated Pharmacological Chaperone AT2220 with
  Recombinant Human Acid Alfa-Glucosidase for Pompe Disease – R. Khanna, S.
  Xu, Y. Lun, R. Soska, J. Feng, M. Frascella, A. Garcia, J. Flanagan, D. J.
  Lockhart, K. Valenzano

  High Incidence of GLA Variants In A Non-Selected Heart Disease Patient
  Population Suggests That The Fabry Trait Is A Common Cardiovascular Genetic
  Risk Factor - R. Schiffman, S. Forni, C. Swift, X. Wu, D. J. Lockhart, M.
  Chee, T. Kitaoka, E. Chudin, S. Pond, N.H. McNeill, K. Sims, E.R. Benjamin,
  L. Sweetman

  The Origins of Glucosylsphingosine in Gaucher Disease – J. Flanagan, B.
  Ranes, N. Brignol, R. Hamler, S.W. Clark

Oral Platform Presentations:

  A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating
  Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in
  Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M.
  Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T.
  Mozaffar, E. Finanger, F. Johnson, P. Boudes

    *Friday, February 15, 2013, 9:15-9:30am ET (Mark Tarnopolsky, McMaster
      University)

  Phase 3 Study of Migalastat HCl for Fabry Disease: Stage 1 Results.– K.
  Nicholls, D.P. Germain, C. Feliciani, S. Shankar, F. Ezgu, S.G. Janmohamed,
  S.M. Laing, R. Schroyer,A.C. Bragat, S. Sitaraman,P. Boudes

    *Friday, February 15, 2013, 10:30-10:45am ET (Fatih Ezgu, Gazi
      University)

Conference Call and Webcast:

John F. Crowley, Chairman and Chief Executive Officer, and members of the
Amicus executive team will host a conference call and live audio/visual
webcast on Friday, February 15, 2013 at 11:30am ET to discuss the data
presented at LDN WORLD.

Interested participants and investors may access the conference call at 11:30
a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).
A live audio webcast can also be accessed via the Investors section of the
Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days.
The slide presentation for the conference call/webcast will also be available
at http://ir.amicustherapeutics.com/events.cfm. Web participants are
encouraged to go to the web site 15 minutes prior to the start of the call to
register, download and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at
2:30 p.m. ET on February 15, 2013. Access numbers for this replay are
855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code
97505816.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
orally-administered, small molecule drugs called pharmacological chaperones, a
novel, first-in-class approach to treating a broad range of human genetic
diseases. Amicus' late-stage programs for lysosomal storage disorders include
migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl
co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry
disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 relating to clinical
development of Amicus' candidate drug products and the timing and reporting of
results from clinical trials evaluating Amicus' candidate drug products. Words
such as, but not limited to, "look forward to," "believe," "expect,"
"anticipate," "estimate," "intend," "plan," "targets," "likely," "will,"
"would," "should" and "could," and similar expressions or words identify
forward-looking statements. Such forward-looking statements are based upon
current expectations that involve risks, changes in circumstances, assumptions
and uncertainties. The inclusion of forward-looking statements should not be
regarded as a representation by Amicus that any of its plans will be achieved.
Any or all of the forward-looking statements in this press release may turn
out to be wrong. They can be affected by inaccurate assumptions Amicus might
make or by known or unknown risks and uncertainties. For example, with respect
to statements regarding the goals, progress, timing and outcomes of
discussions with regulatory authorities and the potential goals, progress,
timing and results of clinical trials, actual results may differ materially
from those set forth in this release due to the risks and uncertainties
inherent in the business of Amicus, including, without limitation: the
potential that results of clinical or pre-clinical studies indicate that the
product candidates are unsafe or ineffective; the potential that it may be
difficult to enroll patients in our clinical trials; the potential that
regulatory authorities may not grant or may delay approval for our product
candidates; the potential that preclinical and clinical studies could be
delayed because we identify serious side effects or other safety issues; the
potential that we will need additional funding to complete all of our studies
and, our dependence on third parties in the conduct of our clinical studies.
Further, the results of earlier preclinical studies and/or clinical trials may
not be predictive of future results. In addition, all forward looking
statements are subject to other risks detailed in our Quarterly Report on Form
10-Q for the quarter ended June 30, 2012. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement, and Amicus undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date hereof.
This caution is made under the safe harbor provisions of Section21E of the
Private Securities Litigation Reform Act of 1995.

FOLD–G

CONTACT: Investors/Media:
         Sara Pellegrino
         spellegrino@amicusrx.com
         (609) 662-5044
 
Press spacebar to pause and continue. Press esc to stop.